Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma.

Asian Pacific journal of cancer prevention : APJCP - 1 Sept 2022

Sabunga Olivia Desty, Kaelan Cahyono, Zainuddin Andi Alfian, Sungowati Ni Ketut, Cangara Muhammad Husni, Miskad Upik

Abstract excerpt

OBJECTIVE: This study evaluated the differences between IDH1-R132H and CD133 expression in different categories of astrocytoma. MATERIAL AND METHODS: This study used a cross-sectional design. Sixty-seven paraffin embedded block of Diffuse Astrocytoma (DA), Anaplastic Astrocytoma (AA) and Glioblastoma (GB) were assessed using using the monoclonal antibody IDH1-R132H and Rabbit polyclonal antibody CD133. RESULTS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Astrocytoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Cross-Sectional Studies

Share to Glioblastoma

Share to Isocitrate Dehydrogenase

Share to Neoplastic Stem Cells

Share to Rabbits

Source

Open in PubMed Open full text

Identifiers

PMID: 36172668
DOI: 10.31557/APJCP.2022.23.9.3051
PMCID: PMC9810319

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma.PMID 36172668Read ↗

IDH1 mutation diminishes aggressive phenotype in glioma stem cells.Semantic proximity Read ↗

Exploring the regulatory role of isocitrate dehydrogenase mutant protein on glioma stem cell proliferation.Semantic proximity Read ↗

Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.Semantic proximity Read ↗

Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas.Semantic proximity Read ↗

Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain ReactionSemantic proximity Read ↗

[Astrocytoma, IDH-Mutant].Semantic proximity Read ↗

MiR-148a increases glioma cell migration and invasion by downregulating GADD45A in human gliomas with IDH1 R132H mutations.Semantic proximity Read ↗

Dual phenotypes in recurrent astrocytoma, IDH-mutant; coexistence of IDH-mutant and IDH-wildtype components: a case report with genetic and epigenetic analysis.Semantic proximity Read ↗

Malignant clinical features of anaplastic gliomas without IDH mutation.Semantic proximity Read ↗

IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.Semantic proximity Read ↗

The Overall Survival Rate Prognosis in Diffuse Astrocytic Patients Based on Isocitrate Dehydrogenase-1 Mutation Status (IDH1 R132H): An Indonesian Multicenter StudySemantic proximity Read ↗

Isocitrate Dehydrogenase-1 Mutations as Prognostic Biomarker in Glioblastoma Multiforme Patients in West BohemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.